News &amp; Updates

The combination of cognitive training and vortioxetine therapy appears to be effective in stemming age-related cognitive decline in older adults, suggests a recent study.

Vortioxetine with cognitive training may prevent age-related cognitive decline

FUTURE shines bright for secukinumab in psoriatic arthritis

24 Apr 2020 by

The phase III FUTURE 2 trial has shown the ability of the bDMARD*, interleukin(IL)-17A inhibitor secukinumab to provide sustained improvements across multiple clinical domains in patients with psoriatic arthritis (PsA) with consistent safety over 5 years.

FUTURE shines bright for secukinumab in psoriatic arthritis

Nonaspirin NSAIDs help prevent postcolonoscopy CRC

Use of nonsteroidal anti‐inflammatory drugs (NSAIDs), except aspirin, is associated with a lower risk of colorectal cancer (CRC) after a negative baseline colonoscopy, a recent study reports.

Nonaspirin NSAIDs help prevent postcolonoscopy CRC

Antibiotics, steroids benefit COPD patients regardless of severity

Both antibiotics and systemic corticosteroids reduce treatment failure rates in patients with chronic obstructive pulmonary disease (COPD), regardless of severity of exacerbations, according to a systematic review and meta-analysis of randomized trials.

Antibiotics, steroids benefit COPD patients regardless of severity

Bedaquiline, delamanid both effective against multidrug-resistant tuberculosis

The new drugs bedaquiline and delamanid appear to be safe and effective in patients with tuberculosis resistant to multiple treatments, according to the results of a study conducted in South Korea.

Bedaquiline, delamanid both effective against multidrug-resistant tuberculosis

Ticagrelor benefits in TWILIGHT hold up in diabetes

Dropping aspirin after 3 months of dual therapy with ticagrelor reduced bleeding in patients with diabetes who have undergone PCI* vs taking both agents for 1 year, the TWILIGHT-DM** study has shown, consistent with benefits seen in TWILIGHT for other high-risk patients.

Ticagrelor benefits in TWILIGHT hold up in diabetes

Ticagrelor monotherapy outshines DAPT after complex PCI

Among patients undergoing complex percutaneous coronary intervention (PCI) who completed 3 months of dual antiplatelet therapy (DAPT) comprising aspirin and the potent P2Y12-receptor inhibitor ticagrelor, aspirin withdrawal led to fewer bleeding episodes without increasing the risk of ischaemic events compared with continued DAPT, according to data from the TWILIGHT-COMPLEX* subanalysis presented at ACC.20/WCC Virtual.

Ticagrelor monotherapy outshines DAPT after complex PCI

UC remission after anti-TNF failure more achievable with vedolizumab vs infliximab

Ulcerative colitis (UC) patients with a primary nonresponse to an antitumour necrosis factor (anti-TNF) are more likely to achieve clinical remission with vedolizumab than with infliximab, as shown in a recent study.

UC remission after anti-TNF failure more achievable with vedolizumab vs infliximab

Microbiome drug for reducing CDI recurrence safe, may be more effective at higher doses

SER-109, an investigational microbiome drug consisting of a consortium of bacterial spores from healthy donors to prevent recurrent Clostridioides difficile infection (CDI), has shown a favourable safety profile in a phase II trial. Early engraftment of SER-109 dose-species helps reduce the risk of recurrence, although engraftment kinetics suggests a higher dosing to increase efficacy.

Microbiome drug for reducing CDI recurrence safe, may be more effective at higher doses

TICO backs ticagrelor alone in ACS post-PCI

Taking ticagrelor alone — and dropping aspirin — after 3 months of DAPT* post-PCI** significantly reduced bleeding events without increasing the risk of ischaemic adverse events compared with continuing a DAPT of ticagrelor plus aspirin, the TICO*** trial has shown.

TICO backs ticagrelor alone in ACS post-PCI